Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant698 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02132468 | A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers(GI-NETorPNET) | completed | Phase 2 | 18 | Mateon TherapeuticsINDUSTRY | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00903396 | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer | terminated | Phase 2 | 7 | Alliance for Clinical Trials in OncologyOTHER | 1 |
| Nov 24, 2017 |
| clinicaltrials |
| NCT02215447 | A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas(NABNEC) | unknown | Phase 2 | 4 | Barwon HealthOTHER_GOV | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00374140 | Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer | completed | Phase 2 | 40 | Ahmad TarhiniOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT02351128 | Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues(PHRC-Merkel) | completed | Phase 2 | 35 | University Hospital, GrenobleOTHER | 1 | Oct 18, 2017 | clinicaltrials |
| NCT00003496 | Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer | terminated | Phase 2 | 4 | Burzynski Research InstituteOTHER | 1 | Sep 28, 2017 | clinicaltrials |
| NCT01340794 | Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma | terminated | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 3 | Sep 21, 2017 | clinicaltrials |
| NCT03279614 | Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma | unknown | Phase 2 | 45 | Peking UniversityOTHER | 1 | Sep 12, 2017 | clinicaltrials |
| NCT02876081 | Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex(THEN) | withdrawn | Phase 2 | 0 | Fondation Hôpital Saint-JosephOTHER | 1 | Sep 11, 2017 | clinicaltrials |
| NCT02995187 | Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC) | unknown | Phase 2 | 25 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT01987232 | Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer | completed | Phase 1 / Phase 2 | 32 | AmgenINDUSTRY | 3 | Aug 28, 2017 | clinicaltrials |
| NCT01441297 | BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer | completed | Phase 2 | 24 | Ji-youn HanOTHER_GOV | 1 | Aug 25, 2017 | clinicaltrials |
| NCT00828139 | S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 189 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT02425072 | NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | John VillanoOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT03219762 | Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC(Nabster) | unknown | Phase 2 | 65 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Jul 26, 2017 | clinicaltrials |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 0 | Jul 19, 2017 | clinicaltrials |
| NCT00856830 | Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | University of Alabama at BirminghamOTHER | 1 | Jul 17, 2017 | clinicaltrials |
| NCT00454324 | Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer(NRR) | terminated | Phase 2 | 30 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT00001191 | The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid | completed | Phase 2 | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00028106 | 131MIBG to Treat Malignant Pheochromocytoma | completed | Phase 2 | 32 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT03204019 | A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor | unknown | Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT00129974 | Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer | terminated | Phase 2 | 1 | Tufts Medical CenterOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT03168607 | Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma | unknown | Phase 2 | 45 | Peking UniversityOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT00043862 | The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)((SCLC)) | completed | Phase 2 | 60 | GlaxoSmithKlineINDUSTRY | 1 | May 31, 2017 | clinicaltrials |
| NCT01166191 | Concurrent Chemo-radiotherapy With Intensity-Modulated Radiation Therapy (IMRT) for Limited Disease Small Cell Lung Cancer (LD-SCLC) | completed | Phase 2 | 60 | Maastricht Radiation OncologyOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT00519896 | Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer | completed | Phase 2 | 35 | University of WashingtonOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT01758458 | Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma | terminated | Phase 1 / Phase 2 | 4 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT01719861 | Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors | terminated | Phase 2 | 6 | Joel NealOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT00947167 | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | terminated | Phase 2 | 4 | Pamela L. KunzOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00050349 | EPO906 in Carcinoid and Other Neuroendocrine Tumors | completed | Phase 2 | 33 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 1, 2017 | clinicaltrials |
| NCT00398320 | Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors | completed | Phase 2 | 40 | Pamela L. KunzOTHER | 1 | Mar 1, 2017 | clinicaltrials |
| NCT00118248 | Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00093782 | Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01640847 | MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases | withdrawn | Phase 2 | 0 | ImunonINDUSTRY | 0 | Feb 7, 2017 | clinicaltrials |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | terminated | Phase 2 | 2 | Emory UniversityOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT01731925 | A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors(SUNLAND) | unknown | Phase 2 | 44 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 2 | Jan 31, 2017 | clinicaltrials |
| NCT00965250 | Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2016 | clinicaltrials |
| NCT01374451 | Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET(COOPERATE-2) | terminated | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 19 | Dec 20, 2016 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT02980809 | Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer | unknown | Phase 2 | 60 | First Hospitals affiliated to the China PLA General HospitalOTHER_GOV | 0 | Dec 2, 2016 | clinicaltrials |
| NCT02972320 | Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic | unknown | Phase 2 | 60 | Yunpeng LiuOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02755675 | uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung | unknown | Phase 2 | 120 | Rigshospitalet, DenmarkOTHER | 1 | Nov 21, 2016 | clinicaltrials |
| NCT02943798 | Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma | unknown | Phase 2 | 118 | Shanghai Chest HospitalOTHER | 0 | Oct 25, 2016 | clinicaltrials |
| NCT02906384 | Memory and MRI Changes With Hippocampus Avoidance Prophylactic Cranial Irradiation(HA-PCI) for Small Cell Lung Cancer(SCLC) | unknown | Phase 2 | 154 | Zhejiang Cancer HospitalOTHER | 1 | Oct 10, 2016 | clinicaltrials |
| NCT02078843 | Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors(GaIN) | terminated | Phase 1 / Phase 2 | 54 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT01221675 | TF2- Small Cell Lung Cancer Radio Immunotherapy | completed | Phase 1 / Phase 2 | 18 | Centre René GauducheauOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT01620138 | Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | completed | Phase 2 / Phase 3 | 21 | Universidade Federal do Rio de JaneiroOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT01045421 | Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies | completed | Phase 1 / Phase 2 | 273 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 15, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Dec 5, 2017source: clinicaltrials